PALO ALTO, Calif.—Agilent Technologies announced it has acquired Boulder, Colo.-based SynPro Corp., which manufactures short nucleic acid molecules for use by the biopharmaceutical industry. It has also hired the existing staff of 22. The acquisition provides Agilent with a value-added opportunity for its existing platforms that support this industry. According to company estimates, the current nucleic acids synthesis market is approximately $700 million, with an estimated growth potential of 10 to 20 percent per year.
"Agilent has identified RNA synthesis as an excellent growth opportunity," said John Eaton, Agilent vice president, Corporate Development. "Acquiring SynPro is a strategic move for us. We are gaining first-rate manufacturing capabilities and deep expertise that will open the door for Agilent to an exciting new market."
